November 17, 2014
OrthoTrophix Completed Patient Treatments in
February 20, 2014
OrthoTrophix Initiated Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis and Closed
OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage and teeth. The primary focus of OrthoTrophix is regeneration and repair of cartilage in the knee and other joints. The company’s leading therapeutic compound, TPX-100, has demonstrated sound safety and efficacy in rebuilding of articular (hyaline) cartilage in the goat knee, believed to be one of the most rigorous cartilage defect models. Human safety studies have been performed in normal volunteers. OrthoTrophix has initiated a Phase 2 proof of concept clinical study of TPX-100 in human patients suffering from knee osteoarthritis in the U.S.